Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Average Rating of “Buy” from Analysts

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has received a consensus rating of “Buy” from the seven research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and two have given a strong buy rating to the company.

A number of equities analysts have recently commented on BAYRY shares. Zacks Research lowered Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. JPMorgan Chase & Co. upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Finally, Barclays upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th.

Bayer Aktiengesellschaft Price Performance

OTCMKTS BAYRY opened at $12.68 on Thursday. Bayer Aktiengesellschaft has a 1 year low of $5.30 and a 1 year high of $13.00. The company has a fifty day simple moving average of $10.27 and a 200 day simple moving average of $8.80. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10. The company has a market cap of $49.16 billion, a P/E ratio of -140.87, a P/E/G ratio of 4.74 and a beta of 0.66.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.